In a concession to drug companies, Senate Democrats reportedly have agreed to delay by one year—from Jan. 1, 2023 to Jan. 1, 2024—the effective date of language in the $1.9 trillion COVID-19 relief bill that might lead to 340B ceiling
…Category: Legislative
Safety-net hospitals, health centers, and HIV/AIDS clinics yesterday applauded the 226 U.S. representatives—more than half of the House’s members—who signed Friday’s bipartisan letter to U.S. Health and Human Services (HHS) Acting Secretary Norris Cochran seeking “immediate action to ensure that
…
Two hundred and twenty six U.S. House members—173 Democrats and 57 Republicans—have signed a letter to U.S. Health and Human Services (HHS) Acting Secretary Norris Cochran asking him “to take immediate action to ensure that manufacturers are prohibited from imposing
…
Today is the deadline for U.S. House members to sign a bipartisan letter asking U.S. Health and Human Services Department (HHS) leaders to act against drug manufacturers denying 340B pricing on drugs, to halt attempts to turn 340B into a
…
The U.S. Senate Finance Committee’s new Democratic chair is considering bringing back a bipartisan bill from the last session of Congress that would require drug manufacturers to pay the federal government rebates on Medicare Part B and Part D drugs
…
President Biden’s pick to serve as U.S. Health and Human Services (HHS) secretary expressed his support for the recent HHS advisory opinion on contract pharmacy during questions today before a key congressional committee.
California Attorney General Xavier
…
The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee this morning is holding the first of two Senate committee hearings this week on President Biden’s nomination of California Attorney General Xavier Becerra to serve as U.S. Health and Human
…
Greg Walden (Ore.), the former Republican chair of the U.S. House Energy and Commerce (E&C) Committee, yesterday launched his own public policy and political strategy firm in partnership with one of Washington’s top lobbying firms.
Walden and the Alpine Group
…
The U.S. Congressional Budget Office (CBO) estimates that eliminating the limit on rebates that drug manufacturers pay to Medicaid, now capped at 100 percent of a drug’s average manufacturer price (AMP), “would reduce direct spending in Medicaid by $15.9 billion
…